AU626538B2 - Growth inhibiting agent and the use thereof - Google Patents

Description

V

PCI

T

IV'TERNATIONALAPPLICATic A~dP DATE 07/09/89 APPLN. ID 30327 89 PCT NUMBER PCI/US89/00175 (51) International Patent Classification 4 (1I) International Publication Number: WO 89/ 065361I A61 3156,31/15 COB 3/16Al(43) International Publication Date: 27 July 1989 (27.07.89)1 (21) International Application Number: PCT/US89/00 175 (22) International Filing Date: 17 January 1989 (17.01.89) (31) Priority Application Numbers: 145,407 295,638 (81) Designated States: AT (European patent), AU, BE (European patent), CH (European patent), DE lEuro-i pean patent), DK, FR (European patent), GB, GB I (European patent), 1T (European patent), j P, RLUJ (European patent), NL (European patent), SE (European patent).

Published With international search report.

(32) Priority Dotes: (33) Priority Country: 19 January 1988 (19 01.88) January 1989 (10.01.89) (71)(72) Applicants and Inventors: FOLKMIAN. Mloses, Judah [US/US]; 18 Chatham Circle, Brookline, NIA 02146 WEISZ, Paul, Burg [US/US]; 3 Delaware Rim Drive, Yardley, PA 19067 (US).

(74) Agent: MISROCK, Leslie; Pennie Edmonds, 1155 Avenue of the Americas, New York, NY 10036 (US), (54) Title: GROWTH INHIBITING AGENT AND THE USE THEREOF L~ n" ain 6, 7orO (57) Abstract Pathological or otherwise undesirable cell or tissue growth In mammals, including humans, is inhibited by administering thereto a composition exemplified by a water-soluble cyclodextrin sulfate salt, together with a growth-inhibiting organic compound. The growth-inhibiting compound may be a steroi d naving no Inhibiting effect In the absence of or an organic compound which may be an active growth inhibitor, the act, Qn of' which is potentiated by The inven-.

tiorn provides a method for inhibiting angiogenests and, controlling the growth of' tumors as well as treating other diseases and pathological conditions associated with undesired cell or tissue growth, including angiogenesis, -1- PCT/US89/001 7 WO 89/06536 GROWTH INHIBITING AGENT AND THE USE THEREOF 1. FIELD OF TEE INVENTION This invention is concerned broadly with the inhibition of pathological or undesired cell or tissue growth in mammals by use of a new growth-inhibiting composition.

More specifically, the present invention is directed to a growth-inhibiting composition comprising a highly soluble cyclodextrin derivative and a latent or active growthinhibiting compound, and to the use of this composition to inhibit undesired or pathological growth, including angiogenesis which is associated with, inter alia, the growth of malignant tumors.

2. BACKGROUND OF THE INVENTION 2.1. HEPARIN AND INHIBITION OF ANGIOGENESIS Angiogenesis, the induction of growth of new capillary blood vessels, is important in normal processes such as development of the embryo, formation of the corpus luteum and healing of wounds. It is also an important component in pathological processes such as chronic inflammation, certain immune responses, and neoplasia. It is now accepted that angiogenesis is induced by most malignant tumors and that it is necessary for their continued growth and survival. It is also recognized that angiogenesis is a major component of a Snumber of ophthamological pathologies including such as diabetic retinopathy, retrolental fibroplasia and neovascular glaucoma. Additionally, angiogenesis is now recognized as a major component in other non-neoplastic pathological conditions including rheumatoid arthritis, in which abnormal capillary growth can destroy joint cartilage; hemanogiomas, in which abnormal capillary proliferation appears in newborns and can persist for up to 2 years; angiofibromas which develop in the nasopharynx; and psoriasis, in which excessive proliferation and shedding may be dependent on abnormal 7 WO 89/06536 PCT/US89/00175 WO 89/06536 capillary growth in the dermas [see Folkman and Klagsbrun, Science 235:442 (1987)].

It has been previously discovered that heparin (or heparin fragments) and cortisone will co-act together to inhibit angiogenesis. This is described in U.S. Patent Application Serial No. 541,305 filed August 16, 1984, the contents of which are incorporated herein by reference. When administered together to mice with certain kinds of tumors, this combination can inhibit the generation of essential capillary vessels that support tumor growth, and can cause the collapse of the blood supply which supports the tumors.

A review of the history of this discovery and of related subject matter is contained in the publication "How is Blood Vessel Growth Regulated in Normal and Neoplastic Tissue?" Clowes Memorial Award Lecture), Judah Folkman, Cancer Research, 46:467 (1986) the contents of which are incorporated herein by reference for background.

Cortisone is an anti-inflammatory agent that by itself does not have the ability to inhibic capillary growth. It 2has been reported in Shubik et al., J. Nat'l Cancer Inst.

57:769 (1976) that 6 a-methyl prednisolone partially suppressed tumor angiogenesis in hamster cheek pouches under certain conditions, but tumor growth was not stopped. Many other publications have reported continued growth of tumors even in the presence of large amounts of cortisone. It has also been reported tGross et al., Proc. Nat'l. Acad. Sci. USA 78:176 (1981)] that medroxyprogestrone, dexamethasone and to a lesser extent cortisone, inhibited tumor angiogenesis in rabbit corneas, while estradiol and testosterone were 3ineffective.

Aside from cortisone, certain other Steroids are now known to successfully suppress angiogenesis when administered together with heparin or certain heparin fragments. The effective steroids have been referred to as fheparindependent" because heparin was (until now) unique in its -ii -3effect. The findings and the character of desirable angiostatic steroids has been discussed in "A New Class of Steroids Inhibits Angiogenesis in the Presence of Heparin or a Heparin Fragment", R. Crum, S. Szabo and J. Folkman, Science 230:1375 (1985); and in "Angiostatic Steroids", J.

Folkman and D E. Ingber, Annals of Surgery, 206:374 (1987) incorporated herein by reference for background purposes.

;eparin, a mucopolysaccharide, is a constitutent of various tissues, especially liver and lung, and mast cells in several mammalian species. Chemically, it has been described as an a, p glycosidically linked sulfated copolymer of Dglucosamine and D-glucuronic acid. However, although heparin has been used clinically as an anticoagulant for half a century, both the exact structure of heparin and the precise nature by which it acts in blood anti-coagulation have not been discovered. Much of the difficulty in determining the structure of heparin results from its complexity and the fact that it is not a homogeneous, well-defined substance.

Heparin is polydisperse with a molecular weight range from about 5,000 to 40,000. Within a given chain, there are also structural variations such as the varying degrees of sulfation, N-acetylation and C-5 epimerization in the uronic acid residue.

A major disadvan.tage in the use of heparin with a steroid to inhibit angiogenesis results from the fact that 2 heparins manufactured by different processes and different companies revealed quite different aitiangiogenic activities despite similar anticoagulant activities. The precise composition of commercial heparin apparently varies depending 30 on its source and method of manufacture. While some heparins 30 .may be combined with cortisone to inhibit angiogenesis, other heparins are not effective as such. In fact, some heparins in order to be effective may be required in such high doses that administration may cause problems.due to the anticoagulant activity of heparin. A second disadvantage is WO 89/06536 4 PCT/US89/00175 that while heparins apparently can inhibit the growth of responsive tumors when administered in the proper dose range and proper ratio to steroid, and even promote regression at somewhat higher doses and ratios; heparins can also cause resumption of rapid tumor growth when administered at even higher dose levels and-ratios to steroid. The apparent presence of both positive and negative regulators of angiogenesis in heparin may create problems in properly administering the drug. An additional disadvantage derives from the anticoagulant activity of heparin, restricting its use to low dosage levels or to oral administration in order to avoid bleeding. Finally because heparin cannot penetrate the corneal membrane, it cannot be topically applied to the exterior of the cornea for its desired antiangiogenic activity.

2.2. CYCLODEXTRINS Cyclodextrins (hereinafter referred to for convenience as CD or CDs for the singular and the plural, respectively) Sare cyclic oligosaccharides consisting of at least six glucopyranose units. Although CDs with up to twelve glucopyranose units are known, only the first three homologs have been studied extensively. These compounds have the simple, well-defined chemical structure shown in FIG. 1(A).

2The common designations of the lower molecular weight and 7-CDs are used throughout this specification and will refer to the chemical structure shown in FIG. 1(A) wherein n-6, 7, or 8 glucopyranose units, respectively. The initial discovery of the CDs as degradation products of starch was made at about the turn of the century, and Schardinger showed that these compounds could be prepared by the action of Bacillus macerans amylase upon starch, In older literature, the compounds are often referred to as Schardinger dextrins.

They are also sometimes called cycloamyloses.

0 Topographically, the CDs may be represented as 0 torus, as shown in FIG. the upper rim of which is lined with primary -CH2OH groups, and the lower rim with secondary hydroxyl groups. Coaxially aligned with the torus is a channel-like cavity of about 5, 6 or 7.5 A.U. diameter for the and 7-CDs, respectively. These cavities make the cyclodextrins capable of forming inclusion compounds with hydrophobic guest molecules of suitable diameters.

A reasonably large number of CD derivatives have been prepared and described in the :iterature. In general, these chemically modified CDs are formed by reaction of the primary or secondary hydroxyl groups attached to carbons 2, 3 or 6 [FIG. without disturbing the a (1 4) hemiacetal linkages. A review of such preparations is given in "Tetrahedron Report Number 147, Synthesis of Chemically Modified Cyclodextrins", A.P. Croft and R.A. Bartsch, Tetrahedron 39(9):1417-1474 (1983), incorporated herein by reference for background (hereinafter referred to as "Tetrahedron Report No. 147").

In particular, and 7-CD sulfates (Na salt) are 20 *20 shown as Compound Nos. 207, 208, and 209 in Tetrahedron Report No. 147, (supra) Table 26, p.1456. U.S. Patent 2,923,704 to Berger describes the preparation of cycloamylose sulfates. U.S. Patent 4,020,160 to Bernstein et al. and U.S.

S" Patent Nos. 4,247,535 and 4,258,180 to Lewis et al. disclose 25 Sthe use of modified cyclodextran sulfates as complement e inhibitors. U.S. patent 4,383,992 to Lipari describes the preparation of a water-soluble inclusion compound of a steroid and unmodified p-cyclodextrin. U.S. patent 4,596,795 to Pitha discloses the administration (by the sublingual or .buccal route) of sex hormones, particularly testosterone, progesterone and estradiol in the form of their inclusion compounds with hydroxypropyl-p-CD or poly-p-CD. None of the foregoing references are believed to show or make obvious applicants' invention as described and claimed herein.

1i 0A I g WO 89/06536 PCT/US89/0017 WO 89/06536 3. ADVANTAGES AND OBJECTS OF THE INVENTION We have now found that certain simple an, very watersoluble derivatives of the cyclodextrins when administered together with a latent growth-inhibiting steroid such as cortisone or hydrocortisone or with a non-steroidal growthinhibiting organic compound effectively inhibit angiogenesis without exhibiting the undesirable properties of heparin.

One of the objects of the present invention is to provide a novel composition including a derivative of a cyclodextrin and a growth-inhibiting compound, which composition is effective for inhibiting cell or tissue growth, especially angiogenesis, or for treating tumors, in mammals, including humans.

Another object of the invention is to provide pharmaceutical preparations containing a highly water soluble cyclodextrin derivative, especially a cyclodextrin sulfate salt, and one or more steroid compounds.

Another object of the present invention is to provide a method of treating diseases or conditions associated or characterized by angiogenesis by inhibiting undesired angiogenesis in mammals, including humans, in need of such treatment.

A further object of the present invention is to provide a method for treating mammals, including humans, having a tumor burden, to arrest and/or to regress growth of the tumor masses.

These and other objects, aspects and advantages of the present invention will become apparent to those skilled in theart upon reviewing the following description and appended 3claims.

4. SUMMARY OF THE INVENTION This invention provides a composition for inhibiting undesired or pathological cell or tissue growth (including angiogenesis) in mammals, including humans, said composition

N'

-7- WO 89/06536 PCT/US89/00175 comprising active agents consisting essentially of a very water-soluble derivative of A- or 7-cyclodextrin in combination with a latent growth-inhibiting steroid or a non-steroidal growth-inhibiting organic compound.

This invention further provides a method of inhibiting undesired or pathological cell or tissue growth (including angiogenesis) in mammals, including humans, comprising administering thereto a growth-inhibiting amount of active agents consisting essentially of a very water-soluble derivative of 3- or,7- cyclodextrin in combination with a latent growth-inhibiting steroid or a non-steroidal growth-inhibiting organic compound. This method of the invention can be accomplished either by mixing the two active agents and administering the combination via a single route or, alternatively, by administering each of the active agents separately and permitting the combination to form in vivo.

According to the alternative mode, the two active agents can be administered separately via the same or different routes, so long as both agents are thus allowed to be present simultaneously in combination in vivo.

This invention further provides a method of inhibiting angiogenesis in mammals, including humans, comprising administering thereto an angiogenesis-inhibiting amount of a composition comprising xctive agents consisting essentially of a very water-soluble derivative of p- or 7cyclodextrin in combination with at least one angiogenesis inhibitor selected from the group consisting of a latent growth-inhibiting steroid and a non-steroidal growth-inhibiting organic compound, said derivative being characterized by a solubility in distilled water of at least about 20 grams per 100 milliliters of water at 0"C.

This invention further provides a method of inhibiting the pathological growth of smooth muscle cells in mammals, including humans, in need of such treatment, which method comprises administering thereto a growth-inhibiting amount of -8- WO 89/06536 PCT/US89/00175 a composition comprising as active agent a very water-soluble cyclodextrin derivative; preferably very water-solubla cyclodextrin sulfate salt consisting essentially of the sulfated anion of A- or 7 -cyclodextrin associated with a non-toxic physiologically acceptable cation.

BRIEF DESCRIPTION OF THE FIGURES The present invention may be more fully understood by reference to the following detailed description of the invention, examples of specific embodiments of the invention and appended figures in which: FIG. 1(A and B) is a schematic representation of: (A) the chemical structure of 4- and 7- cyclodextrins; and of the three-dimensional shape of these cyclodextrins.

FIG. 2 (A and B) graphically illustrates the effect of 9-cyclodextrin tetradeca sulfate (B-CD-TDS) or heparin on growth of rat aortic smooth muscle cells and calf aortic smooth muscle cells in tissue culture.

FIG. 3(A D) is a photographic representation of the effect of topically administered agents on endotoxin-induced capillary vessel development in the rabbit cornea. Effects of Endotoxin alone Control Group); (B) hydrocortisone alone, (Group P-CD-TDS hydrocortisone, (Group and P-CD-TDS alone (Group 4) Sare shown. See text for experimental details.

FIG. 4 graphically illustrates the effect of implantation of sustained release polymers incorporating various agents on endotoxin-induced capillary blood vessel elongation in the rabbit cornea. Endotoxin alone, (Control Group); p-CD-TDS Cortexolone, (Group 2); Cortexolone alone, (Group and P-CD-TDS alone, (Group See text for experimental details.

-9- ~rm I IPlnn mnl WO 89/06536 r.l/uaoluu*l 6- DETAILED DESCRIPTION OF THE INVENTION The present inventors searched for a compound other than heparin, which would not have the disadvantages of heparin, but which when combined with a steroid would be effective for suppressing undesired or pathological cell or tissue growth including angiogenesis and, therefore, would be effective, inter alia, for controlling or eliminating tumors in mammals, including humans.

SBecause of the known ability of cyclodextrins including f-CD to form water soluble inclusion compounds with steroids, we attempted to make use of mixtures of unmodified CDs with hydrocortisone. However, it was discovered that such mixtures had no effect for suppressing angiogenesis, as ihown by Examples 18-20 (infra, Section 7).

Quite surprisingly, we discovered that highly watersoluble salts of cyclodextrin in combination with a steroid, such as hydrocortisone, were effective for inhibiting angiogenesis. In particular, f-CD tetradeca sulfate (p-CD- TDS) was found to be very effective. In other words, a composition comprising a steroid and a water-soluble cyclodextrin derivative is effective for inhibiting undesired cell or tissue growth, including angiogenesis, and for treating tumors in mammals.

The CD sulfates and other highly water-soluble Sderivatives discussed herein have been found to be repoducible in their effect in the chick chorioallantoic membrane (CAM) assay described below. This assay has been employed as a model assay to detect angiogenic activity of various substances. [Klagsbrun et al., Cancer Res.

16:10(1976)]. Three separate batches of f-CD-TDS prepared by the method described in Example 1(A) were compared in the CAM assay. Results for the three separate batches were indistinguishable. The highly water-soluble CD derivatives mimic the advantageous features of antiangiogenic heparin without its disadvantages. These findings also set aside the p1

J

i notion that heparin is unique in its role in suppressing angiogenesis when combined with a suitable steroid.

We have also found that use of a highly water-soluble CD derivative such as P-CD-TDS together with a non-steroidal compound that inhibits growth in the absence of exogenous heparin, a compound that inherently has soiuie antiangiogenic activity, surprisingly potentiates the antiangiogenic activity of such compound. Examples of such non-steroidal compounds include, but are not limited to proline analogs such as L-2-azetidinecarboxylic acid,

H

N

COOH

(see, infra, Example 24), cishydroxyproline, or 3,4dehydroproline, and transretinoic acid. L-2azetidinecarboxylic acid is described in Merck under Compound 911, which description is incorporated herein by reference.

[See Ingber and Folkman, Lab, Investig. 59:44 (1988) for a description of such non-steroidal growth inhibiting compounds which are proline analogs.) STo clearly distinguish the steroids (which in the absence of exogenous heparin, have no inherent antiangiogenic .activity) from such non-steroidal growth-inhibitory compoundri, the qualifying phrase "latent growth-inhibiting" is used herein. The adjective "non-steroidal" as used herein *means a compound in which carbon ring structure characteristic of a sterol is absent.

S

6.1. WATER-SOLUBLE DERIVATIVES OF CYCLODEXTRINS Highly water-soluble CD derivatives bearing non-ionic and/or ionic substituents are useful for inhibiting undesired Sgrowth according to the present invention. Suitable highly 4 -1r-l1water-soluble CD derivatives include a, p and 7 CD derivatives having non-ionic substituents including but not limited to alkyl substituents such as methyl, ethyl, etc., as well as those in which a number of hydroxyl groups are replaced by other groups so as to increase the hydrophi.L~t activity of the CD. Such groups may include, esters, ethers, thioesters, thioethers, carboxylic acids or other groups which convey hydrophilic activity by way of polar or hydrogen bonding constituents or they may include partial hydroxyl substitution that allows better hydrogen bonding involving the remaining hydroxyl groups.

The CD derivatives useful in the present invention are highly hydrophilic and therefore very water soluble, Without wishing to be bound by theory, we believe that a highly hydrophilic character is important to allow interaction with cellular surfaces. We also believe a very high water Ssolubility of the derivative is an important factor which cooperatively interacts with the inherent compleXing ability of the CD structure to provide effective inhibition of angiogenesis with an exogenous steroid, as provided by this invention. We believe that the hydrophilic activity is roughly indicated by the affinity to water, as measured by water solubility. It is important to measure the same at QC since at higher temperatures the most Suitable derivative have solubilities so high that meainingful measurments are r ".25 2* difficult, S: As shown in Table III (Examples 18-22, infra, section the most soluble derivatives (measured at Q0c) show the h highest bntiangiogenic activity. Of the CDs, the p-CD derivatives appear to be most effective, In general, useful 30 po o30 potency is evident at a solubility, measured at O'C, of at leas about 15 gm/100 ml in distilled water, preferably at least about 20 gm/100 ml, more preferably about 30 gm/100 ml.

SAll solubility measurements referred to herein relate to the Ssolubility of the substantially anhydrous derivatives, and ."cen V fteC tutr oprvd fetv niiino -12when these are salts, to the anhydrous sodium form. The term least 15 gm/100 ml measured as described above.

It is contemplated that very water-soluble CD derivatives bearing ionic and/or non-ionic substituents may r some instances have advantageous properties, and that these are within the scope of this invention. Although highly water-soluble derivatives in general are believed useful, salt derivatives are preferred.

The phrase "salt derivative" as used herein means an ionic compound derived from a CD by reaction with a suitable reagent. The preferred salt derivatives are provided by a cyclodextrin having substituents selected from the group onsisting of sulfate, phosphate, carboxylate and mixtures thereof associated with a non-toxic, physiologically 1 acceptable cation. Many of said preferred derivatives are known compounds. (See, Tetrahedron Report Number 147, supra). Btut many potentially useful forms may be variants, structurally or chemically of known compounds. They also may possess several different substituents such as is the case of 20 t20 cehe cyglodextrin propoxyl sulfate of Example ID, which we believe has not previously been reported. Some of the preferred salt forms of the derivatives are the sodium and potassium forms, since these tend to impart increased water *solubility to organic anions. The salt derivatives useful 2 5 *herein will exhibit electrolytic conductivity and osmotic 9. properties characteristic of electrolytes and polyeleotroiytes when in aqueous solution. A particularly preferrz'd salt derivative is P-cyclodextrin tetradeca sulfate

(P-CD-TDS).

30 The P- and 7 -CD sulfate salts are all Usable in the presently claimed invention. P-CD sulfate salts are preferred. Various degrees of sulfation per glucose unit can be employed, sUch as average of one sulfate group per two glucose units of two sulfate groups per glucose unit.

%LI* 2 i WO 89/06536 -1 3- PCTIUS89/00175 Cyclodextrins having about two sulfate groups per glucose "nit are prefeirred. Especially preferred is A-CD-TDS which an average of two sulfate groups per glucose unit.

6.2. STEROIDS AND NON-STEROIDAL ORGANIC COMPOUNDS Among the steroids which are effective and can be utilized in the presently claimed invention are the following: 17 alpha, 21-dihydroxy-4-pregene-3, 11, 20-trione and its 21acetate (or cortisone); 11 alpha, 17,21-trihydroxypregn-4-ene-3,20-dione (or 11 alpha hydrocortisone); 11 beta, 17 aloha, 21-trihydroxypregn-4-ene-3,20-dione (or hydrocortosone); 17 alpha, 21-dihydroxypregna-4, 9(11) -diene-3,20-dione; alpha, 17 alpha, 21-trihydroxy-4-pregnene-3,20-dione; 16 alpha, 17 alpha, 21-trihydroxy-6 aipha-methylpregn-4-eie- 3,20-dione-21-acetate-16,l7 cyclic ketal of acetone; 6 alpha-f luoro-17 alpha, 21-dihydroxy-lE beta-methyl-pregna- 4,9 (11) -dinene-3 6 alpha-fluoro-18 alpha, 21-dihydroxy-16 beta-methyl-pregna- 4,9 (11) -c..4ene-3 ,20-dione-17,21-diacetate; 6 beta, 17 alpha, 21-trihydroxypregn-4-enle-3,29-dione; 17 alpha, 2 1-dihydroXypiregn- 4-ene- 3, 2 0-di one- 21 -acetate; 17 alpha, 21-dihydro.ypregn-4-ene-3,20-,dione (br Cortexolone)16 9 beta, 11 beta-epoxy-1i alpha, 21-dihydroxy-2 alphamethylpregn-4-ene-3 ,20-dione-? 1-acetAte; 17 alphaw, 21-dihydroxy-16 alpha-methylpregn-4 -ene--43 f,20-di one; 309 alpha, 11 beta-dichloro-17 alpha, 21-dihydroxypregp-46ene- 3 ,20-dione-211-acetate 17 alpha, 21-dihydroxy-6 alpha, 16 alpha-dimethylpregn-4ene-3 ,20-dioie-2 1-acetate; 17 alpha, 21-dihydroxy-16 alpha-methylpregna-4, 9(11) -diene- 3, 20-dione-21-acetate; W89056-14- PCT/US89/O0l 7 17 alpha, 21-dihydroxy-16 beta-methylpregna-4, 9f11) -diene- 3, 20-dione-21-benzoate; 6 alpha-fluoro-17 alpha, 2 1-dihydroxy-16 beta -methyi1pregna 4 ,9 (11) -diene-3 ,20-dione-17-acetate-21-benzoate; 17 alpha, 21-di1hydrox-16 beta-methylpregna-i, 4,9 triene-3, 20-dione-17-succinate sodium monohydrate; 9 alpha-fluoro-li beta, 16 alpha, 17 aloha, 21-tetrahydroxypregn-4-ene-3 ,20-dione-16, 21-diacetate; 17 alpha, 21-dihydroxy-16 alpha-methylpregna-l, 4,9(11)- 1triene-3 ,20-dione-21-succinate sodium monohydrate; 6 alpha- fluoro-1.7 A:lpha, 21-dihydroxy-16 beta -methyl -pregna 1,4,9 (11)-triene-3,20-dione-21-succinate sodium; desoxycorticosterone; testosterone;, estro,.e; and tetrahydro S.

More preferred are those steroids which lack glucocorticnid and mineral o-corti1coid activityf since such activity is an undesired effect and limits the c4ose size or extent of use of the steroid f or the purpose of the present invention. Among such more preferred steroids are 11 alpha, 17,21-trihydroxypregn-4-ene-3,20-dione (or 11 alphahydrocortisone), 17 alpha, 21-dihydroxypregn-4-ene-3 (il-desoxycortisol or Cortexolone), and 17 alpha, 21dihydroxypregna-4 9 (11) -diene-3 None of the steroids themselves effectively inhibits angioqenesis nor Oauses regression of tumors in the absence of a water-soluble cyclodextrin derivative of the present invention* As taught by the present invention, the growthinhibitory activity of non-steroidal organic compounds is potentiated by combi1nation with a water-soluble cyclodextrin derivative. Among the non-steroidal growth- inhibiting organic compounds which are effective and can be utilized in 3the presently claimaer. invention are the followingo praline WO 89/06536 -15- PCT/US89/00175 analogs such as L-2 azetidinecarboxylic, cishydroxyproline, and 3,4-dehydroproline and transretinoic acid acid.

Additionally, any non-steroidal organic compound which in ctmbination with a cyclodextrin derivative demonstrates growth inhibiting activity in either of the bioassays described below can be utilized in the methods of the presently claimed invention.

Several bioassays have been developed to estimate the angiogenic-inhibiting potency, if any, of a substance. The rabbit cornea is the basis of one of these methods. The cornea is avascular. A small pocket can be made in it and a tumor implant can be inserted while the rabbit is anesthetized. The tumor is separated from the vascular bed of the host. New capillary blood vessels will grow in a linear manner toward the tumor, and the rate of vessel growth can be measured. [For a more detailed description of this assay, see, Gimbrone et al., J. Nat'l Cancer Inst. 52:413 (1973) incorporated herein by reference].

A more economic bioassay makes use of the chorioallantoic membrane of the chick embryo. This test will for convenience be referred to hereinafter as the "CAM assay". For a more detailed description of the CAM assay, see Folkman et al., Science 221:719 (1983), incorporated herein by reference. A typical CAM assay, such as used for the evaluations in the examples in Section 7, infra, employs 16 eggs per experiment. A 2 mm diameter disk of methylcellulose containing the test substance is applied to the chorioallantoic membrane of a 6-day chick embryo, cultured in a Petri dish, in a humidified incubator with 3% carbon dioxide. Two days later (8-day embryo), the membrane is examined under a stereomicroscope at six- to ten-fold magnification. Inhibition of angiogenesis by the test substance is evidenced by the development of an avascular zone around the methylcellulose disc. An avascular zone of 4 mm is graded as and an avascular zone of 2 mm is graded -16- WO 89/06536

P

1 CT/US89/0017 at The potency of the inhibition at the 2 mm and 4 mm zone(s) are expressed as the percentage of the total number of eggs (usually 16) in the test that were rated or the of "successes". A rating of zero reflects absence of inhibition of the test substance under the test conditions.

The sustained release methylcellulose discs are prepared by dispersing appropriate amount of the test substance of substances in an 0.45% aqueous solution of methylcellulose, and. depositing 10 microliter aliquots of the resulting solution in a Teflon mold, followed by air drying for about one hour in a laminar flow hood.

A very advantageous feature of the CAM assay is the very high sensitivity of the chick embryo to toxic substances. Moreover, the lack of toxicity of a substance in the CAM assay has been correlated with lack of toxicity of such substance when administered to other animals.

6.3. APPLICATIONS AND METHODS OF USE The composition of the present invention is useful for inhibiting undesired cell and tissue growth, including angiogenesis. Of course, the composition of the present invention comprising a wa ,er soluble derivative of an por i-CD and a steroid is to be administered to mammals including humans in need of such treatment. For example, mammals with tumors are in need of treatment with the composition of the present invention. While not completely understood, it is believed that treatment with the composition of the present invention inhibits the creation of new capillaries necessary for tumor growth. This results in the tumor having an insufficient supply of nutrients essential for its growth or even for its vitality. Thus, tumors in mammals including humans, when treated in accordance with the present invention, do not grow and may even lose their vitality and die. Among the tumors WO 89/06536 PCT/US89/00175 contemplated as responsive to the composition and methods of this invention are Reticulum Cell Sarcoma, Lewis Lung Carcinoma, B-16 Melanoma, and Eladder Carcinoma, etc.

Neither mature non-growing blood vessels nor vascular tissue appear to be affected by the treatment with the composition of the present invention. Inhibition of angiogenesis in accordance with the present invention, in addition to its effect upon tumor regression and metastasis in tumor-bearing animals, may be effective in treating a number of other ailments.

The present invention further provides a method for treatment of a number of other non-tumorous disorders which are characterized by pathological cell or tissue growth, including angiogenesis. Thus the invention provides a method for treatment of mammals, including humans, afflicted with a number of non-neoplastic pathological conditions including rheumatoid arthritis, in which abnormal capillary growth can destroy joint cartilage; hemanogiomas, in which abnormal capillary proliferation appears in newborns and can persist for up to 2 years; angiofibromas which develop in the nasopharynx; psoriasis, in which excessive proliferation and shedding may be dependent on abnormal capillary growth in the dermis. Additionally, the present invention provides a method for treatment of a number of ophthalmological 26 pathologies which are associated with undesired angiogenesis, including diabetic retinopathy, retrolental fibroplasia and neovascular glaucoma.

The present invention further provides a method for inhibiting undesired smooth muscle cell development often observed following an ?(iplasty or treatment to remove atherosclerotic plaques which occlude blood vessels.

According to one embodiment of the method of the present invention, the active agents are mixed together prior to administration so that the steroid compound or nonsteroidal growth-inhibiting compound is administered in WO8906536 -18- PCT/US89/00175 combination with the water-soluble cyclodextrin derivative.

After the mixture is prepared, it may be administered orally or parenterally including, inter alia, topical application, intravenous, intra-arterial or subcutaneous injection, and including absorption as well as injection and introduction into body apertures or orifices.

Cortisone and its physiologically accepted non-toxic derivatives, such as the acetates, as well as many other steroids useful in the present invention, are only slightly soluble in water. However, when combined with the watersoluble cyclodextrin derivatives of the invention, the resulting complexes have increased water solubility.

Accordingly, the composition of the present invention can easily be administered. The term "cortisone" and "hydrocortisone" and 1l-a isomer of hydrocortisone as used in the present specification and claims are intended to include both the steroids themselves and their derivatives and structural variants.

According to an alternate embodiment of the method of the invention, the active agents are each administeead separately and the combination of the two agents forms in vivo. In this embodiment, the two active agents can be introduced separately either via the same or different routes of administration, so long as both agents are thus present simultaneously in vivo, permitting a complex mixture of the two active agents to form.

Dosages employed are limited only by the well-known li'its of the administration of drugs individually for their usual effects, in the case of cortisone, hydrocortisone, or 11-a isomer. Since the CD derivatives useful herein have no anticoagulant effect and show no toxicity in the CAM test at dosages employed according ti the method of the invention (see below), they may be administered percutaneously in dosages at least as large as those acceptable for heparin.

Oral dosage may be considerably higher. Simple testing, for WO 89/06536 -9PCT/US89/00175 example by the procedure of Example 3 in U.S. Patent Application Serial Number 641,305, filed August 16, 1984, suffices to determine effectiveness and optimum dose. The procedure of Example 3 is incorporated herein by reference.

The dose amount required to bring about arrest of tumor growth or regression of tumors varies depending upon the identity of the tumor, as does the length of time required to bring about arrest or regression of tumors.

Tumor size at the beginning of treatment also affects the length of time for complete regression. Because administration of cortisone, with or without p-CD-TDS(Na), for example, may result in pulmonary infection after a number of days, it may be desirable to administer a suitable antibiotic as prophylaxis during treatment in accordance with the present invention. Such antibiotics can be mixed with the water-soluble cyclodextrin derivative and the steroid or non-steroidal growth-inhibiting agents of the invention and administered as a mixture or, alternatively, the antibiotics can be administered alone contemporaneously with the watersoluble cyclodextrins and growth-inhibiting agents of the invention either by the same or a different route of administration.

As shown in Table I, infra Section 7, it appears that a weight ratio greater than about 2:1 or a molar ratio of greater than about 0.4 of water-soluble CD derivative to steroid leads to a decrease of antiangiogenic activity.

The preferred molar range and the molar ratio of CD derivative to aingiostatic agent (steroidal or non-steroidal) is QOAatpaboutQ97. A more preferred useful range is about 0.04 to about 0.7. The latter range is particularly useful in topical applications, including as eye drops for ophtalamological uses. The amount of angiostat will generally be of the order of 0.1 to 10 mg/ml when admixed with the CD derivative, however, the absolute amount may depend on the mode and frequency of administration -1 WO89/06536 20- PCT/US89/00175 The effective compositions of this invention are best administered in a suitable carrier, which must be non-toxic and physiologically acceptable, such as water or normal saline solution. Compositions containing mixtures of the active agents or each of the active agents alone, either dry or in a suitable carrier, can be employed.

7. EXAMPLES The following examples are provided to illustrate this 0 invention. However, they are not to be construed as limiting the scope of the invention, which scope is determined by this entire specification including the appended claims. All amounts and proportions shown are by weight unless explicitely stated to be otherwise. For the CAM assay, however, refers to the number of "successes. (See Section 6.3, above).

Examples 1 (A-D) This example illustrates the best mode known to us for preparing and purifying cyclodextrin sulfates. The method is not per se considered part of the present invention.

CD-TDS(Na): ip-cyclodextrin (99% pure dihydrate) was purchased from Chemalog (a division of Genei l Dynamics Corp.), South Plainfield, New Jersey.

grams of P-cyclodextrin (4.4 mmoles, about 92 meq -OH) was dissolved in 250 ml of dimethylformamide (DMF). To this solution was added 15.0 grams of (CH 3 3

N-SO

3 (108 mmoles) in a single portion and the reaction mixture was ShLaated to 70C. After two hours at 70*C, a gummy material began to precipitate. The reaction mixture was maintained at with vigorous stirring, and then cooled to room temperature. The DMF layer was then decanted and discarded, and the solid residue was dissolved in 250 ml of water 3 n Ii c WO 89/06536 -21- CT/US89/00175 followed by addition of 75 ml of 30% sodium acetate. The mixture was stirred vigorously for 4 hours and then poured into 4000 ml of ethanol. After standing overnight, the mixture was filtered to recover the crystallized solids. The filter cake was washed with ethanol (absolute) followed by diethyl eZher. The product was then dried under vacuum over P205. 10.3 grams of white powder was recovered. The product was hygroscopic.

The product was analyzed under conditions such that sorption of water was minimized. Elemental analysis gave the following results: C=18.84, H=2.65, S=17.33 (Calculated for 22 CGH 0 1

S

2 Na 2 C=19.67, H=2.19, S=17.49). 75 (C=2.63 in 0.5 M NaCl). The analysis corresponds to that expected for an average substitution of two hydroxyl groups for each glucopyranose unit, 14 hydroxyls per CD molecules. The calculated yield for such A-CD-TDS salt is 10.96 grams, about 6% higher than the observed 10.3 grams.

a- and 7-CD-S (Na salt): The procedure described above was used for these preparations except that 86 mmoles of CH N-SO 3 was used with a-CD, and 117 mmoles with the 7-CD.

The sulfated a-CD salt analyzed C=18.76; H=2.60; S-16.22. This corresponds on average to a substitution of 2about 11.7 hydroxyl units per a-CD molecule.

The sulfated 7-CD salt analyzed C=18.92; H=2.69; S=14.84. This corresponds on average to a substitution of about 14 hydroxyl groups per 7-CD molecule.

g CD-SO 4 salt) (7.1 wtt S): gm of p-cyclodextrin was dissolved into $0 ml of DMF. To this solution was added 883 mg of (CH 3 3

N'SO.

3 (7.2 equivalents). The solution was held at 75*C for 12 hours, at which time no precipitate had formed. The reaction mixture Swas cooled to room temperature. To the solution was added

I

~ii I WO 89/06536 -22- PCT/US89/00175 200 ml of ethanol. The resulting colloidal solution was then poured into 600 ml of diethyl ether. A white solid formed in 2 hourj. The solid was collected by filtration and then was dissolved in 30 ml H 2 0. This solution was stirred for 2 hours. After stirring, the solution was poured into 900 ml of a 2:1 StOH-E20 solution. Crystals formed over an 8 hour period. The crystals were collected and washed with Et 2 The product was dried over P 2 0 5 under vacuum. 1.18 gm of powder was recovered. (72.4% yield).

Elemental analysis of the product showed C=32.49; H=4.99; and S=7.06. This corresponds on average to a substitution of about 3.5 hydroxyls per p-CD molecule.

9-CD-Propoxylate -14 SO4 A-CD-(hydroxy-n-propyl ether) was obtained from American Maize-Products Co. (Hammond, IN) and the procedure described above was used to prepare the sulfate salt, P-CD- (-4Pr-14

SO

4 Examples 2-15 In these examples the angiogenesis-inhibiting potency of hydrocortisone with various dosage levels of p-CD-TDS prepared as in Example 1 was evaluated by the CAM assay. The methylcellulose discs all contained 60 pg of the steroid but the P-CD-TDS was varied from 100 pg down to 0.05 pg. The results are summarized in Table I. As can be seen from the data, angiogenesis inhibition persists with extremely low levels (0.05 pg) of the CD compound with no evidence of activation of angiogenesis at two thousand-fold higher Sconcentration.

(x

U

4 -23- PCr/US89/ 00175' WO 89/06536 TABLE I CAM Assay Example No. Hydrocortisone Beta-CD-TDS 2 6 0 100 57 3 tv50 60 100 4 50 22 *25 10 6 25 1s 7 10 40 a 10 6 9 1W5 0 N 1 0 11 It1 0 42 12 Is0.5 0 13 0.1 0 14 0.1 0 37 150.05 0 In contrast with these results, CAM tests made with 100 pg of fl- or cyclodextrin with 50 14g of hydrocortisone all showed total absence of 4kngiogenesisinh ibition (no successes at either the I. mm tone or the 2 7mm zone level].

ExaMples 16-17 Examples 16 and 17 illustrate the low, but useful, activity afforded by the sulfated a-CD and 7-CD as shown in Table 11. Date for Examples 5 and 6 are included for comparison. All tests were made with 25 Aig of the indicated CD sulfate and 50 pq of cortisone.

-24- 0S

C

0#* C. C C

C*

C.

C

C

C

C

S* C C

C

C

C.

C

C

C*

C.

C C C C

C

C@

C C C C

CC

C

C

TABLE II CAMI Assay Example CD Sulfur, No. lqt%% 16 AlIpha 16.2 8 0 17 Gamma 18.9 15 0 Beta-CD-TDS 17.3 60 6 Beta-CD-TDS 17.3 55 18 Examples 18-22 This group of examples shows that the angiogenesis suppression activity requires, aside from the characteristic complexing activity of the CD structure, a high water solubility. The CAM assays were made with a dosage of 50 pg to 60 pg of hydrocortisone in 10 pl of (:k45% methylcellulose in water.

In order to make comparisons that included the very Water-soluble CD sulfates, the solubilities of which were so 20 high at room temperature that measurement was not practical, all solub:;Aility measvirements Were made in liquid water at zero cQ, One pan pi&Lure this to be a measur'e of the comipetition of the hydrophilic bonding with water in relation to the orderly u2n fwtrt itself. These comparisons are 25 summarized iLn Ta ble III.

Examples 18, 19 and 20 describe the results for the unsubotituted CDs, which, gave no indication of angiogenesis suppression activity in tiie CAM assay. Example 21 shows the results for a samople of propoXylated. P-CD (hydroxy-n-propyl 30 ether) obtained from American Maize-Produots Co. (Hammond, IN), reported to have an average of about 4 hydtoxypro;yl groups per CD molecule. Examples 2Z shows the results obtained with the less sulfated p-CD product from Ex~mple 1(C) above. The results for Examples, 16, 17 and WO 89/ 06536 PCT/US89/00175 including water solubilities at zero Are included to complete the comparison.

77r c ii i i .i WO 89106536 PCT!US89/1oo7$ TABLE III CAM Ass~ays ex Nor pgund 18 a-CD 19 O-CD y-CD Conc.

100 100 100 No.

Exxa~vpes Avascular zones 5+ 0.3 0 0 0.04 0 Solubility, qLI00 ml H 22 0.7 0.7 *t 21

O-CD-

4 Pr) 21a -iJ-Di4ke 14 Meth) 100 100 25 100 25 s 9.7 22+ 5.7 20+ 9.6 840 3.1 37 2Q 32+ 32+ 13 13 39 22 P-CD- 7 S04) 21a fl-C-D 4 propoxylated) 14 sO 4 16 a-CD 12 S04) 100 17± 4.7 4+ 2.7 314 5.1 19+ 1v .6

SO

4 1o 24 100 19 20 101 107

P-CD"TDS

55+ 75+ 58+ 5.8 insufifiient mteria avgilable for s6o 7 Lubiity determination.

i

L

i Pt :i tWO89/06536 -27- PCT/US89/00175 Example 23 This example illustrates that Cortexolone with p-CD- /TDS is an exceptionally effective antiangiogenic composition.

Cortexolone is closely related to cortisone chemically.

However, it possesses almost none of the functions of cortisone, except for the antiangiogenic effect in the presence of heparin.

Cortexolone, 50 #l/10 pl alone, gave zero avascular zones in the CAM assay.

At the same dosage level, with 25 pg/lO pl of B-CD- TDS, the CAM assay showed 85% avascular zones of which 31% are or greater.

Exampla 24 This example demonstrates that the angiostatic activity of L-2-azetidinecarboxylic acid, which has some inherent angiostatic activity, is strongly potentiated by the presence of CD-TDS. The results of the CAM assay, in the absence and presence of CD-TDS, are given in Table IV, Examples 24(a) and 24(b), respectively.

s I 1 -28- PCT/US39/00175 WO 89/06536 TABLE IV: L-2-AZETIDINE jl g CD-TDS Avascular Zones L-2-Azetidine 400 0 28 I-2-Azetidine 400 25 100 of these avascular zones were and 25% were 3+, the largest avascular zones ever observed, greater than 10 mm.

Example This example demonstrates the P-CD-TDS is about three times as effective as whole heparin in suppressing smooth muscle cell (SMC) growth when each is used alone without exogenous corticosteroid or other supplementation).

The bioassay of this activity was made using tissue cultures of rat aortic SMC and calf aortic SMC, with dosages ranging from 0.03 pg/ml up to 400 pg/ml.

The results are shown graphically in FIG. 2(A) and Example 26 This example demonstrates that topical administration 2of p-C-TDS in combination with hydrocortisone effectively inhbits neovascularization in the cornea.

The rabbit corneal test described by Perlin, Fed.

Proc. 36:101 (1977) modified as described below, was employed to examine the effectiveness of a combination of B-CD-TDS and hydrocortisone. In this corneal test, a sustained release 'polymer impregnated with bacterial endotoxin was first Simplanted in rabbit corneas. Endotoxin slowly released from this implant induces angiogenesis in the cornea in a manner analogous to the neovascularization observed in patients rejecting a corneal transplant. Rather than employing a ii -29- WO 89/06536 PCT/US89/00175 second implant containing the test substance to deliver such test, substance as generally used, in the present experiments the test substance was applied topically to the cornea, i.e., in the form of eye drops. Animals having received an endotoxin-containing implant were divided into four groups and were treated by topical application (eye drops) as follows: Group 1, was not treated further and served as the control group; Group 2, received hydrocortisone alone (0.5 mg/ml); Group 3, hydrocortisone-21-phosphate and O-CD-TDS, (0.5 mg/ml and 1.0 mg/ml, respectively); and Group 4, p-CD-TDS mg/ml). The diluent for the eye drops was saline in all cases. FIG. 3 illustrates the results typically obtained on the 9th day post-implantation and treatment.

As shown in the photographs of FIG. 3, a combination of hydrocortisone and O-CD-TDS when topically applied to the cornea was very effective in inhibiting angiogenesis (FIG.

3C). The efficacy of this treatment is particularly apparent when the results obtained are compared to those observed in the untreated or control group (FIG. 3C vs FIG. 3A). In fact, in animals treated with hydrocortisone and O-CD-TDS, capillary growth was not only inhibited, but also new capillaries which had formed before initiation of the treatment regressed (FIG. 3C). On the other hand, hydrocortisone alone produced only a slight inhibition of angiogenesis (FIG. 3B). P-CD-TDS alone caused a slight stimulation of angiogenesis (FIG. 3D).

In another series of experiments, the antiangiogenic activity cf a water-soluble cyclodextrin salt derivative in combination with cortexolone was evaluated using the rabbit cornea test as described by Gimbrone et al., J. Nat'1 Cancer Inst. 52:413 (1974). In these experiments, E. coli endotoxin (17 pg/mm incorporated into sustained release polymer pellets of ethylene vinylacetate copolymer (Elvax, Sigma Chemical, St. Louis, MO (hereinafter "Elvax")] was implanted 89/06536 -30- PCT/US89/001 7 wo 89/06536 between the vascular limbal edge of the rabbit corneas. The test substance(s) were administered by means of a second Elvax implant incorporating the particular test substance.

Elvax containing endotoxin was implanted into the corneas of 12 rabbits. The animals were then divided into 4 groups and 4 eyes were treated for each group as follows: Group 1, received no further treatment and served as the control group; Group 2, 8-CD-TDS at 15 g/mm 3 Elvax pellet; Group 3, cortexolone at 30 pg/mm 3 Elvax pellet; and Group 4, a combination of p-CD-TDS and cortexolone incorporated into an Elvax pellat at a final concentration of 15 pg/mm Elvax of P-CD-TDS and 30 pg/mm Elvax of cortexolone. The vessel length of new capillary growth was measured every 2 days with a slit-lamp stereoscope at 10X using an ocular grid calibrated to 0.1 mm.

Measurement of vessel length alone underestimates the extent of antiangiogenic activity because such measurement does not assess capillary density. Thus, the vessel density was also evaluated and graded using the following scale: 0=no vessels/cornea; 1-1-4 vessels/cornea; 2=5-20 vessels/cornea; 3-20-50 vessels/cornea; and 4-more than 50 vessels/cornea.

This grade was then multiplied by mean maximal length of the vessels to obtain a semi-quantitative estimate of vessel debsity (length-density index) for each cornea. Results obtained are graphically illustrated in FIG. 4 and tabulated in Table V.

As demonstrated in FIG. 4, the largest difference between treated and control corneas was observed on day 13 after implantation of the Elvax pellets. The mean vessel 3 lengths and vessel density observed on day 13 are listed in STable V.

WO 89/06536 PCT/US89/00175 TABLE V INHIBITION OF ANGIOGENESIS IN CORNEAS Inhibition of Untreated Control Group B-CD-TDS Cortexolone 9-CD-TDS Cortexolone Alone Alone Vessel Length 18% 49% 164% Vessel Density 8% 61% 303% a Percentage greater than 100% represents stimulation of vessel development.

As shown in Table V, a combination of 8-CD-TDS and cortexolone inhibited linear capillary blood vessel growth to about 18% of that observed in untreated eyes. When capillary density was estimated, this combination suppressed vessel density to about 8% of that observed in untreated eyes. In contrast, as shown in Table V, when administered alone, cortexolone inhibited linear vessel growth only to about 49% and vessel density to about 61% that observed in untreated eyes. Surprisingly, as further demonstrated in Table V, administration of g-CD-TDS alone, stimulated vessel growth by about 164% and vessel density by about 303% above that observed in untreated eyes.

Based on these results, it is clear that administration of a cyclodextran salt derivative in combination with a steroid according to the present invention, is an effective method for inhibiting angiogenesis in ophthalmological tissues.

(I (a

Claims (24)

1. A composition for inhibiting undesired or pathological cell or tissue growth, including angiogenesis, in mammals, including humans, comprising a ionic derivative of 3- or y-cyclodextrin in combination with a latent growth-inhibiting steroid or a. non-steroidal growth- inhibiting organic compound, in which the said derivative is characterized by a solubility at 0 0 C in distilled water at least about 20 gm/100 ml of water.

2. A composition according to claim 1, in which the derivative of 1- or y-cyclodextrin is sulfate, phosphate, carboxylate or mixtures thereof associated with physiologically acceptable cation. :0. S*ii

3. A composition according to claim 2, in which the derivative of 13- or y-cyclodextrin is a cyclodextrin sulfate.

4. A composition according to claim 2 or claim 3, in which the cyclodextrin sulfate is 8-cyclodextrin tetradeca sulfate. *9*

5. A composition according to claim 1, in which the steroid has 17-alpha and 21-hydroxyl groups, 3- and groups and in the 16-position hydrogen, hydroxy or a methyl group and non-toxic, physiologically acceptable carboxylates, acetal, ketals and phosphates thereof.

6. A composition according to claim 3, in which the steroid has 17-alpha and 21-hydroxyl groups, 3- and groups and in the 16-position hydrogen, hydroxy or a methyl group and non-toxic, physiologically acceptable carboxylates, acetal, ketals and phosphates thereof.

7. A composition according to claim 4, in which the steroid has 17-alpha and 21-hydroxyl groups, 3- and VA4 groups and in the 16-position hydrogen, hydroxy or a methyl 0 A O 1 -33- group anad non-toxic, physiologically acceptable carboxylates, acetal, ketals and phosphates thereof.

8. A composition according to claim 7, in which the steroid is cortisone, hydrocortisone or cortexolone.

9. A composition according to claim 1, in which the non-steroidal growth-inhibiting organic compound is L-2- azetidinecarboxylic acid and the derivative of cyclodextrin is a cyclodextrin sulfate.

A method for inhibiting undesired or pathological tumor growth, by means of inhibiting angiogenesis associated with a tumor, in mammals, including humans, in need of such, comprising administering to a mammal, including humans, having a tumor a tumor growth-inhibiting amount of active agents consisting essentially of derivative of a-, S* 3 or y-cyclodextrin in combination with a latent growth-inhibiting steroid or a non-steroidal growth-inhibiting organic compound, the derivative being characterized by a solubility at 0*C in distilled water of at least about gm/100 ml of water.

11. A method for inhibiting angiogenesis in mammals, including humans, in need of such, comprising administering to a mammal, including humans, an angiogenesis- inhibiting amount of active agents consisting essentially of a derivative of B- or y-cyclodextrin in combination with a latent growth-inhibiting steroid or a non-steroidal growth-inhibiting organic compound, the derivative being characterized by a solubility at 0°C in distilled water of at least about 20 gm/100 ml of water.

12. A method according to claim 10, in which the derivative of 8- or y-cyclodextrin is a sulfate, phosphate, carboxylate or mixtures thereof associated with a non-toxic physiologically acceptable cation. i

13. A method according to claim 11, in which the t~n I M -34- derivative of B- y-cyclodextrin is a sulfate, phosphate, carboxylate or mixtures thereof associated with a non-toxic physiologically acceptable cation.

14. A method according to claim 12 or 13, in which the salt of B- or y-cyclodextrin is a cyclodextrin sulfate.

A method according to claim 12 or 13, in which the salt is B-cyclodextrin sulfate.

16. A method according to claim 10 or 11, in which the steroid has 17-alpha and 21-hydroxyl groups, 3- and groups and in the 16-position hydrogen, hydroxy or a methyl group and non-toxic, physiologically acceptable carboxylates, acetal, ketals and phosphates thereof. .f

17. A method according to claim 10 or 11, in which the steroid is cortisone, hydrocortisone or cortexolone.

18. A method according to claim 10 or 11, in which the non steroidal growth-inhibiting organic compound is Q L-2-azetidinecarboxylic acid.

19. A method for inhibiting the pathological growth of smooth muscle cells in mammals, including humans, comprising administering to a mammal, including humans, in C* need of such, a growth-inhibiting amount of a derivative of a, 3- or y-cyclodextrin, the derivative being characterized by a solubility at 0°C in distilled water of at least about gm/100 ml of water.

A method according to claim 19, further comprising administering an amount o a latent growth-inhibiting steroid or a non-steroidal growth-inhibiting organic compound, the derivative being characterized by a solubility at 0 C in distilled water of at least about gm/100 ml of water. lo i l vrc^ r

21. A composition for inhibiting undesired or pathological cell or tissue growth, including angiogenesis, in mammals, including humans, comprising a derivative of a-, B- or y-dyelodextrin in combination with a latent growth-inhibiting steroid or a non-steroidal growth-inhibiting organic compound, in which the derivative is characterized by a solubility at o°C in distilled water at least about 20 gm/ml of water, and in which the molar ratio of cyclodextrin derivative to a latent growth-inhibiting steroid or a non-steroidal growth-inhibiting organic compound is about 0.004 to about 0.7.

22. A composition according to claim 21, in which the steroid has 17-alpha and 21-hydroxyl groups, 3- and groups and in the 16-position hydrogen, hydroxy or a methyl group and non-toxic, physiologically acceptable carboxylates, acetal, ketals and phosphates thereof.

23. A composition according to claim 22, in which *oi 0 the steroid is cortisone, hydrocortisone or cortexolene.

24. A composition according to claim 1 substantially as hereinbefore described. 0t r 9 ^U t4